Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer

BACKGROUND: Bacillus Calmette-Guérin (BCG) unresponsive/relapsing patients with non-muscle invasive bladder cancer (NMIBC) who prefer bladder preservation over radical cystectomy (RC) or those who do not qualify for surgery may be offered intravesical therapies. Gemcitabine (GEM) combined with Docet...

Descripción completa

Detalles Bibliográficos
Autores principales: Milbar, Niv, Kates, Max, Chappidi, Meera R., Pederzoli, Filippo, Yoshida, Takahiro, Sankin, Alexander, Pierorazio, Phillip M., Schoenberg, Mark P., Bivalacqua, Trinity J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676758/
https://www.ncbi.nlm.nih.gov/pubmed/29152553
http://dx.doi.org/10.3233/BLC-170126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676758/
https://www.ncbi.nlm.nih.gov/pubmed/29152553
http://dx.doi.org/10.3233/BLC-170126

Ejemplares similares